Dr. Donald Fleming MD
Director of the Cancer Care Center , DAVIS HEALTH SYSTEM, INC.
Member of the Healthcare Council
Council Member Biography
Donald Fleming, MD, is presently the Director of the Cancer Care Center for the Davis Health System. He was the Head of Hematology-Oncology at the Medical Center of Vincennes until mid 2008. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical trials involving the treatment of hematologic and oncology disorders. Dr. Fleming has also served as consultant for various pharmaceutical companies. (This is me - Update Profile)
Employment History
- 2008 - Unspecified
- Director of the Cancer Care Center , DAVIS HEALTH SYSTEM, INC.
- 2002 - 2008
- Division Head of Hematology and Oncology, MEDICAL CENTER OF VINCENNES
- 1995 - 2002
- Associate Professor of Oncology / Hematology, UNIVERSITY OF LOUISVILLE
GLG NewsSM Analyses by Donald Fleming
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Microarrays and the fingerprints of cancer
July 10, 2011
How Bright Promise in Cancer Testing Fell Apart | www.nytimes.com
Genetic testing in regards too cancer cells has been a long time projectMicroaaray techniques using more reliable RNA versus DNA patterns will likely lead the wayProteionomic is is yet a further downstream approach to classifying cancer uniqueness
-
Profitable palliation of none at all?
July 4, 2011
There is a plethora of new treatments for cancer.Universally new cancer treatments are very expensive.There are as many cancer patients being treated for palliative purposes as cure
-
Avastin: a targeted drug without a target?
June 30, 2011
Breast Cancer Patients Plead for Avastin Approval | www.nytimes.com
Targeted cancer therapy is the trend in oncology therapyAvastin is a targeted therapy that has only theory backing up it's mode of actionAvastin has the benefit and drawback of being designated as broadly active yet specific to no cancer!
-
Tarceva gives more proof: One should know the target for Targeted therapy
June 4, 2011
Roche’s Tarceva Stalls Lung Cancer With Gene Mutation in Late-Stage Study | www.bloomberg.com
So called targeted therapy has been a term coined over the last decade in the approach to treating cancer. A recent Roche study demonstrates almost doubling of disease control when one uses a patient population that has a defined target is treated with the drug Tarceva
-
Necessity may be the mother of invention,but the father is profit.
April 16, 2011
Shortage Worsens of Leukemia Drug | online.wsj.com
There is a shortage of many cancer fighting medications, as more and more of the agents used to treat cancer become generic. The problem is both profit and regulation driven.
GLG Study Groups with Donald Fleming(?)
| Study Group Name | No. Members |
|---|---|
| Oncologists (US) | 2218 |
| Hematologists (US) | 993 |
| Oncologists who Treat Hematologic Malignancies (US) | 851 |
| Oncologists Specializing in Hematologic Malignancies in the U.S. | 413 |
| Council Members who Treat Colon/Colorectal Cancer | 274 |
GLG Live Meetings with Donald Fleming(?)
Donald Fleming has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.